GlassScriptPhysician profile
Andrew S Waters
NPI 1538456025
$11,716.50
in general payments reported to CMS, 2019-2025
50 companies · $1,718 in 2025
The $1,718 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $471 · 2021: $1,904 · 2022: $1,697 · 2023: $3,218 · 2024: $1,737 · 2025: $1,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,746 · Travel and Lodging: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,746.37 |
| Travel and Lodging | $925.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,504.93 | 2021-2025 | Mitraclip, Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Boston Scientific Corporation | $894.61 | 2019-2025 | Farapulse, Watchman Access System, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $822.03 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $679.81 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $637.52 | 2021-2025 | Verquvo, Keytruda, Winrevair |
| E.R. Squibb & Sons, L.L.C. | $616.65 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $591.10 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $565.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $523.64 | 2019-2025 | Farxiga, Andexxa, Lokelma |
| Novo Nordisk INC | $488.71 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.48 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $278.45 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $249.11 | 2019-2025 | Lifevest |
| Amarin Pharma, INC. | $209.35 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $205.13 | 2019-2025 | Onpattro, Amvuttra |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Waters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.